Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV)


Hospital

Location:
Lausanne, Switzerland


Publications in cooperation with FAU scientists


Go to first page Go to previous page 1 of 3 Go to next page Go to last page
Kolios, A.G.A., Hueber, A., Michetti, P., Mrowietz, U., Mustak-Blagusz, M., Sator, P.-G.,... Schiefke, I. (2019). ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study. Journal of the European Academy of Dermatology and Venereology, 33(1), 234-241. https://dx.doi.org/10.1111/jdv.15179
Strnad, P., Buch, S., Hamesch, K., Fischer, J., Rosendahl, J., Schmelz, R.,... Trautwein, C. (2019). Heterozygous carriage of the alpha1-antitrypsin Pi∗Z variant increases the risk to develop liver cirrhosis. Gut, 68(6), 1099-1107. https://dx.doi.org/10.1136/gutjnl-2018-316228
Girard, N., Mornex, F., Christoph, D.C., Fietkau, R., Filippi, A.R., Field, J.,... Garassino, M.C. (2019). PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. In ANNALS OF ONCOLOGY. Geneva, CH: OXFORD: OXFORD UNIV PRESS.
Dey, M., Studer, J., Schaub, M.P., Gmel, G., Ebert, D., Lee, J.Y.C., & Haug, S. (2019). Problematic smartphone use in young Swiss men: Its association with problematic substance use and risk factors derived from the pathway model. Journal of Behavioral Addictions, 8(2), 326-334. https://dx.doi.org/10.1556/2006.8.2019.17
Bernasconi, A., Cendes, F., Theodore, W.H., Gill, R.S., Koepp, M.J., Hogan, R.E.,... Bernasconi, N. (2019). Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force. Epilepsia, 60(6), 1054-1068. https://dx.doi.org/10.1111/epi.15612
Bernasconi, A., Cendes, F., Theodore, W., Gill, R.S., Koepp, M., Hogan, R.E.,... Bernasconi, N. (2019). Response to commentary on recommendations for the use of structural MRI in the care of patients with epilepsy: A consensus report from the ILAE Neuroimaging Task Force. Epilepsia. https://dx.doi.org/10.1111/epi.16324
Pavel, M.E., Dromain, C., Thanh, T.X.M., & Houchard, A. (2019). Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study. In NEUROENDOCRINOLOGY (pp. 157-157). BASEL: KARGER.
Papuc, S.M., Abela, L., Steindl, K., Begemann, A., Simmons, T.L., Schmitt, B.,... Rauch, A. (2019). The role of recessive inheritance in early-onset epileptic encephalopathies: a combined whole-exome sequencing and copy number study. European journal of human genetics, 27(3), 408-421. https://dx.doi.org/10.1038/s41431-018-0299-8
Dromain, C., Pavel, M.E., Ruszniewski, P., Langley, A., Massien, C., Baudin, E., & Caplin, M.E. (2019). Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer, 19(1). https://dx.doi.org/10.1186/s12885-018-5257-x
Lamarca, A., Ronot, M., Moall, S., Crona, J., Opalinska, M., Lopez, C.,... Dromain, C. (2019). Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study. In NEUROENDOCRINOLOGY (pp. 137-137). BASEL: KARGER.
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2019). Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study. Oncologist. https://dx.doi.org/10.1634/theoncologist.2018-0672
Dittmar, D., Uter, W., Bauer, A., Fortina, A.B., Bircher, A.J., Czarnecka-Operacz, M.,... Schuttelaar, M.L. (2018). European Surveillance System on Contact Allergies (ESSCA): polysensitization, 2009-2014. Contact Dermatitis, 78(6), 373-385. https://dx.doi.org/10.1111/cod.12966
Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Koetter, I.,... Schiffrin, E.J. (2018). Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Annals of the Rheumatic Diseases, 77(6), 840-847. https://dx.doi.org/10.1136/annrheumdis-2017-212608
Cazzaniga, S., Apfelbacher, C., Diepgen, T., Ofenloch, R.F., Weisshaar, E., Molin, S.,... Simon, D. (2018). Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. British Journal of Dermatology, 178(1), 229-237. https://dx.doi.org/10.1111/bjd.15660
Crona, J., Lamarca, A., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study. (pp. 171-171).
Lee, M., Wlodarczak, A., Bennett, J., Torzewski, J., Haude, M., Vrolix, M.,... Verheye, S. (2018). Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First 400 Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry. (pp. B142-B143).
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study. (pp. 178-178).
Messerli, F.H., Hofstetter, L., Agabiti-Rosei, E., Burnier, M., Elliott, W.J., Franklin, S.S.,... De Leeuw, P.W. (2017). Expertise: no longer a sine qua non for guideline authors? Journal of Hypertension, 35(8), 1564-1566. https://dx.doi.org/10.1097/HJH.0000000000001435
Lewczuk, P., Lelental, N., Lachmann, I., Holzer, M., Flach, K., Brandner, S.,... Kornhuber, J. (2017). Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimers Disease, 55(1), 159-170. https://dx.doi.org/10.3233/JAD-160448
Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Koetter, I.,... Schiffrin, E. (2017). OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL'S DISEASE. (pp. 709-709).

Last updated on 2016-31-05 at 08:18